Health Blueprint

Back to Longevity News

News summary

Gradient-driven microfluidic framework for the screening of ratiometric drug combinations towards precision oncology in paediatric leukaemia

Source: Nature - Biotechnology • Published: 23 Oct 2026, 00:00

Summarized by Masters of Longevity from Nature - Biotechnology.

Reports a microfluidic GradientScreen that profiles overlapping drug ratios to screen combinatorial responses in pediatric acute lymphoblastic leukemia samples for precision treatment selection.

Gradient-driven microfluidic framework for the screening of ratiometric drug combinations towards precision oncology in paediatric leukaemia
Key Takeaways
  • 6: Combinatorial functional response profiling for improved precision medicine in paediatric ALL.
  • Article CAS PubMed PubMed Central Google Scholar Tourneau, C.
  • Article PubMed PubMed Central Google Scholar Kurtz, S.
Read the full article at Nature - Biotechnology ↗

Continue exploring

Recommended MoL Picks

MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickReducing Inflammation from Ageing Cells: What a Mouse Study FoundResearchers reduced the inflammatory signals released by cells that had stopped dividing. Older mice also improved on some strength and frailty tests. Whether this approach could help people remains unknown.